Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel.
Front Immunol. 2023 Feb 16;14:1151620. doi: 10.3389/fimmu.2023.1151620. eCollection 2023.
Human urinary proteins are a goldmine of natural proteins a feature that simplifies their translation to biologics. Combining this goldmine together with the ligand-affinity-chromatography (LAC) purification method, proved a winning formula in their isolation. LAC specificity, efficiency, simplicity and inherent indispensability in the search for predictable and unpredictable proteins, is superior to other separation techniques. Unlimited amounts of recombinant cytokines and monoclonal antibodies (mAb) accelerated the "triumph". My approach concluded 35 years of worldwide pursuit for Type I IFN receptor (IFNAR2) and advanced the understanding of the signal transduction of this Type of IFN. TNF, IFNγ and IL-6 as baits enabled the isolation of their corresponding soluble receptors and N-terminal amino acid sequence of the isolated proteins facilitated the cloning of their cell surface counterparts. IL-18, IL-32, and heparanase as the baits yielded the corresponding unpredictable proteins: the antidote IL-18 Binding Protein (IL-18BP), the enzyme Proteinase 3 (PR3) and the hormone Resistin. IFNβ proved beneficial in Multiple Sclerosis and is a blockbuster drug, Rebif. TNF mAbs translated into Remicade to treat Crohn's disease. Enbrel based on TBPII is for Rheumatoid Arthritis. Both are blockbusters. Tadekinig alfa™, a recombinant IL-18BP, is in phase III clinical study for inflammatory and autoimmune diseases. Seven years of continuous compassionate use of Tadekinig alfa™ in children born with mutations (NLRC4, XIAP) proved life-saving and is an example of tailored made medicine. IL-18 is a checkpoint biomarker in cancer and IL-18BP is planned recently to target cytokine storms resulting from CAR-T treatment and in COVID 19.
人类尿液蛋白是天然蛋白的宝库,这一特性使其在转化为生物制剂时变得更加简单。将这个宝库与配体亲和层析(LAC)纯化方法结合使用,在其分离中被证明是一个成功的方法。LAC 的特异性、效率、简单性以及在寻找可预测和不可预测蛋白方面的固有不可或缺性,都优于其他分离技术。大量的重组细胞因子和单克隆抗体(mAb)加速了这一“胜利”。我的方法总结了 35 年来全球范围内对 I 型干扰素受体(IFNAR2)的研究,并推进了对这种类型干扰素信号转导的理解。TNF、IFNγ和 IL-6 作为诱饵,使相应的可溶性受体得以分离,而分离出的蛋白的 N 端氨基酸序列则促进了其细胞表面对应物的克隆。IL-18、IL-32 和肝素酶作为诱饵产生了相应的不可预测蛋白:解毒剂 IL-18 结合蛋白(IL-18BP)、酶蛋白酶 3(PR3)和激素抵抗素。IFNβ 在多发性硬化症中被证明是有益的,是一种重磅药物,Rebif。TNF mAbs 转化为 Remicade 用于治疗克罗恩病。Enbrel 基于 TBPII 用于治疗类风湿关节炎。两者都是重磅药物。Tadekinig alfa™,一种重组的 IL-18BP,正在进行 III 期临床试验,用于治疗炎症性和自身免疫性疾病。七年来,对患有突变(NLRC4、XIAP)的儿童持续进行 Tadekinig alfa™的同情使用证明了它的救命作用,这是量身定制药物的一个例子。IL-18 是癌症的检查点生物标志物,最近计划将 IL-18BP 用于靶向 CAR-T 治疗和 COVID 19 引起的细胞因子风暴。